LYZL6

Across TCGA pan-cancer cohorts, LYZL6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LYZL6 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LYZL6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYZL6 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUSC, COAD, and BLCA are the cancer types where LYZL6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.112	0.743	<.001	27	view →
COAD	OS	Median	All	0.168	0.801	.003	24	view →
BLCA	DFS	Median	All	1.000	0.327	.038	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	All	0.031	0.775	<.001	6	view →
LUAD	OS	Median	All	0.292	0.699	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LYZL6–LUSC (OS)

Open the LUSC breakdown →